Cevimeline Market 2023 : Cevimeline (trade name Evoxac) is a parasympathomimetic and muscarinic agonist, with particular effect on M1 and M3 receptors. It is used in the treatment of dry mouth and especially associated with Sjögren’s syndrome.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Cevimeline is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Cevimeline is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Cevimeline is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Cevimeline include Daiichi Sankyo, Novel Laboratories, Rising Pharmaceuticals, West-Ward Pharmaceuticals, Lupin and Sun Pharmaceutical, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Top Key Players:
- Daiichi Sankyo
- Novel Laboratories
- Rising Pharmaceuticals
- West-Ward Pharmaceuticals
- Lupin
- Sun Pharmaceutical
Cevimeline Market By Applications
- Hospital
- Drug Store
Cevimeline Market By Types
- 20mg
- 30mg
Get a Sample PDF of report –https://www.360researchreports.com/enquiry/request-sample/21623845
How much is the Growth Potential of the RFID Sensor Market?
What are some factors restraining revenue growth of the global Modular UPS market?
How much is The Global Basil Seeds Market worth in the future?
How fast is the global Pupilometer Market expected to grow until 2026?
